Alvotech Stock Price, News & Analysis

Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has announced the acquisition of Ivers-Lee Group, a Swiss pharmaceutical assembly and packaging services provider. The acquisition integrates Ivers-Lee's operations into Alvotech's Technical Operations division while maintaining it as a separate legal entity.

The strategic move comes as Alvotech prepares to launch three new biosimilars in 2025. Ivers-Lee's GMP-licensed and FDA-approved facility in Burgdorf, Switzerland, along with its unit in Lörrach, Germany, will provide capabilities including assembly and packaging of autoinjectors, pre-filled syringes, safety devices, and vials. Peter Schüpbach, Ivers-Lee's managing director, will join Alvotech's Technical Operations senior leadership team while continuing to lead Ivers-Lee.

Alvotech (NASDAQ: ALVO) has announced the acquisition of Ivers-Lee Group, a Swiss pharmaceutical assembly and packaging services company. The strategic acquisition integrates Ivers-Lee's operations into Alvotech's Technical Operations division while maintaining it as a separate legal entity.

The acquisition comes as Alvotech prepares to launch three new biosimilars in 2025. Ivers-Lee, founded in 1947, operates from Burgdorf, Switzerland and Lörrach, Germany. Peter Schüpbach, the founder's grandson, will continue as managing director and join Alvotech's Technical Operations leadership team.

The GMP-licensed and FDA-approved Burgdorf facility will provide capabilities including assembly and packaging of autoinjectors, pre-filled syringes, safety devices, and vials. Ivers-Lee will continue serving existing clients and providing CMO services.

Alvotech S.A. has announced that its treasury holdings have increased significantly, with the company now holding 6.73% of its own shares as of June 25, 2025. This represents 22,484,087 shares out of a total of 334,038,147 shares with voting rights, surpassing the 5% threshold that requires disclosure under Luxembourg transparency laws.

Alvotech (NASDAQ: ALVO) reported strong Q1 2025 financial results, with total revenues reaching $132.8 million, a 260% increase year-over-year. Product revenues surged 786% to $109.9 million, while Adjusted EBITDA improved to $20.5 million from negative $38.4 million in 2023.

The company increased its full-year guidance to $600-$700 million in revenue and $200-280 million in adjusted EBITDA, following the acquisition of Xbrane's R&D operations and rights to a proposed Cimzia biosimilar. Notable achievements include the U.S. launch of SELARSDI™ (ustekinumab-aekn), a Stelara® biosimilar, and BLA filing acceptances for biosimilars to Simponi®, Eylea®, and Prolia/Xgeva.

The company reported a net profit of $109.7 million ($0.39 per share) and expects to be free cash-flow positive in 2025.

Alvotech (ALVO) has announced the granting of stock options to four independent board directors and the vesting of previously awarded Restricted Share Units (RSUs). Each director received options to purchase 24,784 Alvotech shares at an exercise price of $9.28 per share.

The stock options will vest over a three-year period, with one-third vesting each year starting from the grant date of June 25, 2025. Directors must remain board members at the time of vesting to exercise their options. The exercise price was determined by the opening price of Alvotech's ordinary shares on Nasdaq US on the grant date.

Alvotech (NASDAQ: ALVO) has entered into a supply and commercialization agreement with Advanz Pharma for AVT10, a biosimilar candidate to Cimzia® (certolizumab pegol). The agreement focuses on the European market and expands the existing strategic partnership between the two companies.

Notably, Alvotech's biosimilar candidate is currently the only one under development globally referencing Cimzia®, a TNF-alpha inhibitor used for treating chronic rheumatic diseases. The reference product Cimzia® generated worldwide sales of US$2.3 billion in 2024.

This agreement adds to the existing partnership between Alvotech and Advanz Pharma, which already covers biosimilar candidates for more than ten reference biologics. The companies anticipate launching their first biosimilars in Europe in Q4 2025.

Alvotech (NASDAQ: ALVO) announced that its lenders have agreed to reduce interest rates on its senior secured term loan facility, resulting in estimated savings of $8.2 million in interest payments over the first 12 months. The agreement reflects the company's improved operational performance and stronger financial position.

The facility, maturing in July 2029, will consolidate its two tranches into a single tranche with an interest rate of SOFR plus 6.0% per annum, down from previous rates of SOFR plus 6.5% and 10.5%. The total facility balance stands at $1,081 million, with a company cash balance of $152 million as of June 25, 2025.

Alvotech (ALVO) held its 2025 Annual and Extraordinary General Meeting on June 25, 2025 in Luxembourg. The company announced that all proposed resolutions on the meeting agenda were successfully approved by shareholders. The official notarized meeting minutes and detailed voting results will be made available on the company's investor relations website.

Alvotech (NASDAQ: ALVO), in partnership with Kashiv Biosciences and Advanz Pharma, announced positive topline results from their confirmatory efficacy study for AVT23, a proposed biosimilar to Xolair® (omalizumab). The study met its primary endpoint, demonstrating therapeutic equivalence and comparable safety to Xolair® in patients with Chronic Spontaneous Urticaria (CSU).

The double-blind study enrolled 600 patients, with 400 receiving the confirmatory dose of 300mg. The primary efficacy measure focused on changes in weekly Itch Severity Score at Week 12. The UK MHRA has already validated the marketing authorization application, with an EMA filing expected by year-end.